Koru Ozgur, Yazici Ertugrul, Rasmussen Charlotte, Ringwald Pascal, Artuk Cumhur, Bedir Orhan
Gulhane Training and Research Hospital, Department of Medical Microbiology, Etlik, Ankara, Turkey.
World Health Organization, 20 Avenue Appia, 1211, Geneva 27, Switzerland.
IDCases. 2019 Oct 10;18:e00607. doi: 10.1016/j.idcr.2019.e00607. eCollection 2019.
Artemisinin-based combination therapy (ACT) is recommended by the World Health Organization as first-line treatment of uncomplicated Plasmodium falciparum malaria. ACT treatments failures among travellers returning from Africa to non-endemic countries are considered to be caused by resistance.
We report on a case of artemether-lumefantrine treatment failure in a Turkish traveller with uncomplicated malaria returning from Bamako, Mali.
Information on returning travellers, includes ensuring that the patients receive supervised treatment with the recommended dose of a quality controlled medicine, routine follow-up of all cases, assessment of adequate absorption of the drug, and/or testing the prevalence of molecular markers of drug resistance if validated, can be an important source of an early warning system for emerging resistance.
世界卫生组织推荐以青蒿素为基础的联合疗法（ACT）作为无并发症恶性疟原虫疟疾的一线治疗方法。从非洲返回非疟疾流行国家的旅行者中出现ACT治疗失败被认为是由耐药性引起的。
我们报告了一例从马里巴马科返回的患有无并发症疟疾的土耳其旅行者使用蒿甲醚-本芴醇治疗失败的病例。
关于返回旅行者的信息，包括确保患者接受推荐剂量的质量控制药物的监督治疗、对所有病例进行常规随访、评估药物的充分吸收情况，以及/或者在验证后检测耐药性分子标志物的流行情况，可能是新兴耐药性早期预警系统的重要信息来源。
